Proteins

Rupintrivir

Cat. No.: HY-106161 CAS No.: 223537-30-2 Molecular Formula: $C_{31}H_{39}FN_4O_7$ Molecular Weight: 598.66

Target: Enterovirus; Virus Protease

Pathway: Anti-infection

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

| | | |) NI | H |
|-----|------|-------|----------------|--------|
| 0-N | NH O | O N H | | 0 0 |
| | | | ↓ _F | |

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (83.52 mM; Need ultrasonic)

| | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| Preparing Stock Solutions | 1 mM | 1.6704 mL | 8.3520 mL | 16.7040 mL |
| | 5 mM | 0.3341 mL | 1.6704 mL | 3.3408 mL |
| | 10 mM | 0.1670 mL | 0.8352 mL | 1.6704 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.67 mg/mL (2.79 mM); Clear solution

BIOLOGICAL ACTIVITY

| Description | Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC ₅₀ of 0.023 μ M. Rupintrivirvr shows immune-modulatory effect ^{[1][2]} . |
|-------------|---|
| In Vitro | In H1-HeLa and MRC-5 cell protection assays, Rupintrivirvr (AG7088) inhibited the replication of all HRV serotypes (48 of 48) tested with a mean 50% effective concentration (EC $_{50}$) of 0.023 μ M (range, 0.003 to 0.081 μ M) and a mean EC $_{90}$ of 0.082 μ M (range, 0.018 to 0.261 μ M) as well as that of related picornaviruses including coxsackieviruses A21 and B3, enterovirus 70, and echovirus 11 $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Rupintrivirvr (AG7088) reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo ^[2] . |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Viruses. 2020 Jun 10;12(6):628.
- Arch Virol. 2021 Oct 4.
- Patent. US20210308117A1.
- Research Square Preprint. 2021 Mar.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Patick AK, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50.

[2]. Danov O, et al. Rupintrivir reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo. Respir Res. 2019 Oct 22;20(1):228.

[3]. Dragovich PS, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem. 1999 Apr 8;42(7):1203-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA